Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

Impact · against what's priced in

The Phase IIb success of tulisokibart is a positive development for MRK but lacks immediate material impact on the stock price. Because the current valuation focuses on Keytruda's patent cliff, the mRNA cancer vaccine, and the Lipfendra launch, a Phase II result for a drug still 2-4 years from potential filing is too distal to shift the current price assumptions.

MRK+0.10

Not in the price yet

In context

The positive Phase IIb results for tulisokibart in HS are not mentioned in the current priced-in reconstruction, which focuses on Keytruda and Lipfendra. While fundamentally positive, the 2-4 year timeline to potential filing makes this a low-impact catalyst relative to the current core drivers.